Granted Patent
B2
US 12,611,409 · App. 17/694,829 · Granted Apr 28, 2026
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
Inventors:
James J. Campbell (San Jose, CA); Zhenhua Miao (San Carlos, CA); Thomas J. Schall (San Carlos, CA); Israel Charo (San Carlos, CA); Shijie Li (Los Altos, CA); Christine Marie Janson (Berkeley, CA); Rajinder Singh (Belmont, CA); Karen Ebsworth (San Francisco, CA)
Assignee:
CHEMOCENTRYX, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
Claims (16)
1 . A method of treating cancer in a mammal, said method comprising administering a therapeutically effective amount of a CCR2 chemokine receptor antagonist and a therapeutically effective amount of a PD-1 and/or PD-L1 inhibitor, wherein said CCR2 chemokine receptor antagonist is Compound 1
or a pharmaceutically acceptable salt thereof;
wherein said cancer is glioma; and
wherein the PD-1 inhibitor is pembrolizumab or nivolumab and the PD-L1 inhibitor is durvalumab, atezolizumab, or avelumab.
2 . The method of claim 1 , wherein said PD-1 and/or PD-L1 inhibitor is a PD-1 inhibitor.
3 . The method of claim 2 , wherein the PD-1 inhibitor is pembrolizumab.
4 . The method of claim 2 , wherein said PD-1 and/or PD-L1 inhibitor is an anti-PD-1 antibody which is Nivolumab.
5 . The method of claim 1 , wherein said PD-1 and/or PD-L1 inhibitor is a PD-L1 inhibitor.
6 . The method of claim 5 , wherein the PD-L1 inhibitor is durvalumab.
7 . The method of claim 1 , wherein the CCR2 chemokine receptor antagonist and the PD-1 inhibitor and/or the PD-L1 inhibitor are administered concomitantly.
8 . The method of claim 7 , wherein the CCR2 chemokine receptor antagonist, and the PD-1 inhibitor and/or the PD-L1 inhibitor are administered in a combination formulation.
9 . The method of claim 1 , wherein the CCR2 chemokine receptor antagonist, and the PD-1 inhibitor and/or the PD-L1 inhibitor are administered sequentially.
10 . The method of claim 9 , wherein the CCR2 chemokine receptor antagonist is administered prior to administration of the PD-1 inhibitor and/or the PD-L1 inhibitor.
11 . The method of claim 9 , wherein the CCR2 chemokine receptor antagonist is administered after the administration of the PD-1 inhibitor and/or the PD-L1 inhibitor.
12 . The method of claim 1 , wherein the CCR2 chemokine receptor antagonist is administered orally and the PD-1 inhibitor and/or the PD-L1 inhibitor is administered intravenously.
13 . The method of claim 1 , wherein the mammal is a human subject.
Assignments (3)
ASSIGNEE CHANGE OF ADDRESS
Recorded Jun 27, 2023
From: CHEMOCENTRYX, INC.
To: CHEMOCENTRYX, INC.
Reel/Frame 064144/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 16, 2022
From: CAMPBELL, JAMES J.; MIAO, ZHENHUA
To: CHEMOCENTRYX, INC.
Reel/Frame 061120/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 16, 2022
From: SCHALL, THOMAS J.; CHARO, ISRAEL; LI, SHIJIE; JANSON, CHRISTINE MARIE; SINGH, RAJINDER; EBSWORTH, KAREN
To: CHEMOCENTRYX, INC.
Reel/Frame 061120/0543 →
Continuity (3)
Provisional Application
62562952
· Sep 25, 2017
References Cited (166)
US 6949546B2
· Ko et al.
· 2005
[cited by applicant]
US 8168757B2
· Finnefrock et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8519135B2
· Chen
· 2013
[cited by applicant]
US 8546408B2
· Krasinski
· 2013
[cited by applicant]
US 8552154B2
· Freeman et al.
· 2013
[cited by applicant]
US 8629133B2
· Sugimoto
· 2014
[cited by applicant]
US 8741295B2
· Olive
· 2014
[cited by applicant]
US 9212224B2
· Cogswell et al.
· 2015
[cited by applicant]
US 9783540B2
· Fan et al.
· 2017
[cited by applicant]
US 20060030582A1
· DeMartino et al.
· 2006
[cited by applicant]
US 20160222060A1
· Miller et al.
· 2016
[cited by applicant]
US 20190269664A1
· Campbell et al.
· 2019
[cited by applicant]
US 20190275015A1
· Campbell et al.
· 2019
[cited by applicant]
US 20200121688A1
· Fan et al.
· 2020
[cited by applicant]
US 20200297708A1
· Harrison et al.
· 2020
[cited by applicant]
US 20220241290A1
· Campbell et al.
· 2022
[cited by applicant]
EA 014960B1
· 2011
[cited by applicant]
JP 2013526507A
· 2013
[cited by applicant]
JP 2013528657A
· 2013
[cited by applicant]
WO 0213824A1
· 2002
[cited by applicant]
WO 03004487A1
· 2003
[cited by applicant]
WO 03092586A2
· 2003
[cited by applicant]
WO 03093231A2
· 2003
[cited by applicant]
WO 03093266A1
· 2003
[cited by applicant]
WO 2004041777A2
· 2004
[cited by applicant]
WO 2004076411A2
· 2004
[cited by applicant]
WO 2004082682A1
· 2004
[cited by applicant]
WO 2004092124A2
· 2004
[cited by applicant]
WO 2004094371A2
· 2004
[cited by applicant]
WO 2004110376A2
· 2004
[cited by applicant]
WO 2005044264A1
· 2005
[cited by applicant]
WO 2005044795A1
· 2005
[cited by applicant]
WO 2005067502A2
· 2005
[cited by applicant]
WO 2005080371A1
· 2005
[cited by applicant]
WO 2005115392A2
· 2005
[cited by applicant]
WO 2006073592A2
· 2006
[cited by applicant]
WO 2006074265A2
· 2006
[cited by applicant]
WO 2008014381A2
· 2008
[cited by applicant]
WO 2008014381A3
· 2008
[cited by applicant]
WO 2010121011A1
· 2010
[cited by applicant]
WO 2011100227A1
· 2011
[cited by applicant]
WO 2011159852A1
· 2011
[cited by applicant]
WO 2013152269A1
· 2013
[cited by applicant]
WO 2014151634A1
· 2014
[cited by applicant]
WO 2015009856A2
· 2015
[cited by applicant]
WO 2015026634A1
· 2015
[cited by applicant]
WO 2015034820A1
· 2015
[cited by applicant]
WO 2015160641A2
· 2015
[cited by applicant]
WO 2015160641A3
· 2015
[cited by applicant]
WO 2016039749A1
· 2016
[cited by applicant]
WO 2016057624A1
· 2016
[cited by applicant]
WO 2016077518A1
· 2016
[cited by applicant]
WO 2016100285A1
· 2016
[cited by applicant]
WO 2016100608A1
· 2016
[cited by applicant]
WO 2016149351A1
· 2016
[cited by applicant]
WO WO2016187393A1
· 2016
[cited by examiner]
WO 2017165125A1
· 2017
[cited by applicant]
WO 2018005374A1
· 2018
[cited by applicant]
WO 2018195283A1
· 2018
[cited by applicant]
WO 2019144098A1
· 2019
[cited by applicant]
Extended European Search Report corresponding to EP 16797279.3 (PCT/US2016033210) dated Oct. 26, 2018; 8 pages.
[cited by applicant]
International Search Report and Written Opinion corresponding to PCT/US2016/033210 mailed Aug. 16, 2016; 8 pages.
[cited by applicant]
International Preliminary Report on Patentability corresponding to PCT/US2016/033210 issued Nov. 21, 2017; 6 pages.
[cited by applicant]
International Search Report and Written Opinion dated Jan. 23, 2019 corresponding to PCT/US2018/052408 filed Sep. 24, 2018; 19 pages.
[cited by applicant]
International Search Report and Written Opinion dated Apr. 18, 2019 corresponding to PCT/US2019/012515 filed Jan. 7, 2019.
[cited by applicant]
Partial Supplementary European Search Report dated May 27, 2021 corresponding to EP Appl 18857688.8 filed Sep. 24, 2018; 19 pages.
[cited by applicant]
Extended European Search Report dated Sep. 14, 2021 corresponding to EP Appl 18857688.8 filed Sep. 24, 2018; 19 pages.
[cited by applicant]
Ahmadzadeh, Mojgan et al., “Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired,” Blood (Aug. 20, 2009); 114(8):1537-1544.
[cited by applicant]
Bonapace, L. et al., “Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis,” Nature (Nov. 6, 2014); 515(7525):130-133; Abstract only.
[cited by applicant]
Broggi, Achille et al., “Preparation of Single-cell Suspensions for Cytofluorimetric Analysis from Different Mouse Skin Regions,”
[cited by applicant]
Butora, Gabor et al., “3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2,”
[cited by applicant]
Cannarile, Michael A. et al., “Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy,”
[cited by applicant]
Carter, Percy H. et al., “Advances in the Discovery of CC Chemokine Receptor 2 Antagonists,”
[cited by applicant]
Carter, Percy H. “Progress in the discovery of CC chemokine receptor 2 antagonists 2009-2012,” Expert Opinion on Therapeutic Patents (published oline Feb. 22, 2013) 23(5):549-568.
[cited by applicant]
Chen, Lieping et al., “Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future,”
[cited by applicant]
Chen, Xuguang et al., “CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice,”
[cited by applicant]
Cherney, Robert J. et al., “Discovery of Disubstituted Cyclohexanes as New Class of CC Chemokine Receptor 2 Antagonists,”
[cited by applicant]
Cheung, K-John J. et al., “Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis,”
[cited by applicant]
Cohen, Ivan J. et al., “Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer,”
[cited by applicant]
De Zeeuw, D. et al., Abstract Only: “The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomized trial,”
[cited by applicant]
Dolan, Dawn E. et al., “PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy,”
[cited by applicant]
Dörwald, F. Zaragoza, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design,
[cited by applicant]
Franklin, Ruth A. et al., “The Cellular and Molecular Origin of Tumor-associated Macrophages,”
[cited by applicant]
Fujimura, Taku et al., “Regulatory T Cells Stimulate B7-H1 Expression in Myeloid-Derived Suppressor Cells in ret Melanomas,”
[cited by applicant]
Fujimura, Taku et al., “Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer,”
[cited by applicant]
Gao, Zhongli et al., “Unraveling the Chemistry of Chemokine Receptor Ligands,”
[cited by applicant]
Gong, Jiang-Hong et al., “An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-Ipr Mouse Model,”
[cited by applicant]
Gopinath Adithya et al., IMMU-09. Disruption of the CCL2-CCR2 Axis Augments the Effects of Immune Checkpoint Inhibitors to Slow Progression of Gliomas.
[cited by applicant]
Grivennikov, Sergei I., et al., “Immunity, Inflammation, and Cancer,”
[cited by applicant]
Guzik, Katarzyna et al., “Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1,”
[cited by applicant]
Hackam, Daniel G. et al., “Translation of Research Evidence from Animals to Humans,”
[cited by applicant]
Hitchcock, Jessica R. et al., “Anti-CCL2: building a reservoir or opening the floodgates to metastasis?”
[cited by applicant]
Hwang, S.T et al., “Mycosis fungoides and Sezary syndrome,”
[cited by applicant]
Janson, Christine et al., “Abstract 5655: Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer,” (Jul. 2017); 77(13):: Abstract 5655; 2 pages.
[cited by applicant]
Jordan, V.Craig, “Tamoxifen: A Most Unlikely Pioneering Medicine,”
[cited by applicant]
Jung, Heiyoun et al., “Abstract A107: Inhibition of CCR@ potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer,” Cancer Immunology Research (Nov. 2016) XP055804244 Retreived from the Internet: URL:http…
[cited by applicant]
Kang, Young Sun et al., “CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nepropathy in type 2 diabetic mice,” Kidney International (published online Aug. 4, 2010); 78:883-894.
[cited by applicant]
Karihaloo, Anil et al., “Macrophages Promote Cyst Growth in Polycystic Kidney Disease,”
[cited by applicant]
Kitagawa, Kiyoki et al., “Blockade of CCR2 Ameliorates Progressive Fibrosis in Kidney,” American Journal of Pathology (Jul. 2004; accepted Mar. 30, 2004); 165(1):237-245.
[cited by applicant]
Kothandaraman, Shankaran et al., “Design, synthesis, and structure-activity relationship of novel CCR2 antagonists,”
[cited by applicant]
Krejsgaard, Thorbjørn et al., “Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover,”
[cited by applicant]
Le, Dung et al., “Abstract CT124: A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorec…
[cited by applicant]
Lim, Jee Woong et al., “Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonsits,”
[cited by applicant]
Lim, Su Yin et al., “Targeting the CCL2-CCR2 signaling axis in cancer metastasis,”
[cited by applicant]
Miura, Kouichi et al., “Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2,”
[cited by applicant]
Miyagaki, T et al., “Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis,”
[cited by applicant]
Moree, Wilna J. et al., “Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series,”
[cited by applicant]
Norman, Peter, “A dual CCR2/CCR5 chemokine antagonist, BMS-813160?”
[cited by applicant]
Nywening, Timothy M., M.D. et al., “Phase 1b study targeting tumour associated macrophages with CCR2 inhibition plus FOLFIRINOX in locally advanced and borderline resectable pancreatic cancer,”
[cited by applicant]
Papadopoulos, Kyriakos P et al., “First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors,”
[cited by applicant]
Pasternak, Alexander et al., “Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist,”
[cited by applicant]
Pasternak, Alexander et al., “Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists,”
[cited by applicant]
Pasternak, Alexander et al., “Conformational studies of 3-amino-1-alkyl-cyclopentane carboxamide CCR2 antagonists leading to new spirocyclic antagonists,”
[cited by applicant]
Pedersen, Martin B. et al., “High intratumoral macrophage content is an adverse prognostic feature in analplastic large cell lymphoma,”
[cited by applicant]
Peranzoni, Elisa et al., “Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment,”
[cited by applicant]
Pienta, Kenneth J et al., “Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCLS), in metastatic castration-resistant prostate cancer,”
[cited by applicant]
Press Release: ChemoCentryx's CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models, (Oct. 18, 2016); 4 pages.
[cited by applicant]
PUBCHEM-‘124’ Create Date: Aug. 9, 2005; Date accessed Jul. 13, 2016; p. 3; compound; 13 pages.
[cited by applicant]
Roblek, Marko et al. “Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis,”
[cited by applicant]
Sandhu, Shahneen K. et al., “A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors,”
[cited by applicant]
Sanford, Dominic et al., “Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Anxis,”
[cited by applicant]
Stanley, E. Richard et al., “CSF-1 Receptor Signaling in Myeloid Cells,”
[cited by applicant]
Steinberg, Shannon M et al., “Myeloid Cells that Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors,”
[cited by applicant]
Sugaya, Makoto et al., “Association of the Nos. of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma,”
[cited by applicant]
Tang, Xiaoqiang et al., “Anti-tumour strategies aiming to target tumour-associated macrophages,”
[cited by applicant]
Trujillo, John I. et al., “Design and synthesis of novel CCR2 antagonists: Investigation of non- aryl/heteroaryl binding motifs,”
[cited by applicant]
Ueno, Takayuki et al., “Significance of Macrophage Chemoattractant Protein-1 in Macrophage Recruitment, Angiogenesis, and Survival in Human Breast Cancer,”
[cited by applicant]
Vestergaard, Christian et al., “Expression of CCR2 on Monocytes and Macrophages in Chronically Inflamed Skin in Atopic Dermatitis and Psoriasis,”
[cited by applicant]
Vippagunta, Sudha R. et al., “Crystalline solids,”
[cited by applicant]
Vogelstein Bert et al., “Cancer genes and the pathways they control,”
[cited by applicant]
Wein, Lironne et al., “Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions,” Frontiers in Oncology (Aug. 3, 2017); 7(156…
[cited by applicant]
Wikipedia article Spartalizumab; https://en.wikipedia.org/wiki/Spartalizumab; CAS No. 1935694-88-4; accessed Jun. 29, 2020 (1 page).
[cited by applicant]
Wu, Xuesong et al., “Upregulation of Inflammatory Cytokines and Oncogenic Signal Pathways Preceding Tumor Formation in a Murine Model of T-Cell Lymphoma in Skin,”
[cited by applicant]
Wu, Xuesong et al., “Depletion of M2-Like Tumor-Associated Macrophages Delays Cutaneous T-Cell Lymphoma Development In Vivo,”
[cited by applicant]
Wu, Xuesong et al., “Cutaneous T-Cell Lymphoma: The Yin and Yang of Inflammation and Neoplasia,”
[cited by applicant]
Xue, Chu-Biao et al., “Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist,”
[cited by applicant]
Xue, Chu-Biao et al., “Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist,”
[cited by applicant]
Yang, Li et al., “Tumor-associated macrophages, potential targets for cancer treatment,”
[cited by applicant]
Yao, Min et al., “Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts,”
[cited by applicant]
Yao, Wenbo et al., “A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer,”
[cited by applicant]
Zhang, Jian et al., “Targeting chemokine (C—C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic,” Prog Mol Biol Transl Sci (2010); 95:31-53. doi: 10.1016/B978-0-12-385071-3.00…
[cited by applicant]
Zheng, Yi et al., “Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists,” Nature (Dec. 15, 2016); 540(7633):458-461.
[cited by applicant]
FDA; OPDIVO (nivolumab) injection, for intravenous use Initial U.S. Approval: 2014; Obtained from accessdata.fda.gov <URL: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&Appl No= 125527…
[cited by applicant]